Elekta (EKTA) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
5 Mar, 2026Executive summary
Solid quarter with 2% net sales growth at constant currency, driven by Europe and China, but reported sales declined by 10% due to currency effects.
Strong commercial momentum in Europe and China, with the U.S. showing double-digit order growth year-to-date but negative sales growth in Q3.
SEK 417 million restructuring charge recognized, with over 80% of planned changes executed and annual cost savings expected to exceed SEK 500 million.
Product launches, especially Evo in the U.S. and China, supported improved gross margin despite FX and tariff headwinds.
Focus on innovation, localization in China, and commercial execution in the U.S. as key strategic priorities.
Financial highlights
Net sales increased by 2% year-over-year in constant currency, reaching SEK 4,239 M; reported sales declined by 10% due to FX.
Adjusted gross margin improved to 38.3% (from 37.1%), aided by product launches and pricing, despite FX and tariff headwinds.
Adjusted EBIT margin rose to 11.9% (from 11.7%), with EBIT at SEK 504 M.
Cash flow after continuous investments was SEK 255 M for Q3, with year-to-date improvement of SEK 443 M; net debt decreased to SEK 3,819 M.
Adjusted EPS was SEK 0.88 (down from SEK 0.94 year-over-year); net income dropped to SEK 12 M (from SEK 336 M).
Outlook and guidance
Full-year 2025/26 outlook reiterated: net sales expected to grow year-over-year in constant currency.
Continued negative impact on earnings from FX and tariffs anticipated.
Midterm targets include gross margin returning to pre-pandemic levels and EBIT margin reaching 14% or higher.
Full run-rate cost savings from restructuring expected in Q1 2026/27.
Latest events from Elekta
- SEK 500m+ savings, job cuts, and innovation drive target growth in China and US.EKTA
Strategy update2 Feb 2026 - Sales up 5% year-over-year, but Q4 declined; margin recovery expected in H2 2024/25.EKTA
Q4 23/2431 Jan 2026 - Net sales up 1% with strong U.S. growth and a major Mexico order; margin recovery expected.EKTA
Q1 24/2523 Jan 2026 - Sales and margins declined, but new products and cost savings are set to boost performance.EKTA
Q2 24/2512 Jan 2026 - AI-driven adaptive radiotherapy and software boost growth, margins, and global adoption.EKTA
Investor update10 Jan 2026 - Record cash flow and European growth offset US and China weakness; margin guidance lowered.EKTA
Q3 24/2527 Dec 2025 - Margins improved, cash flow strengthened, and major cost-saving actions launched.EKTA
Q2 25/2626 Nov 2025 - Net sales up 3% in constant currency, margins down, net income up 50%, cash flow improved.EKTA
Q1 25/2623 Nov 2025 - Margin expansion, software growth, and profitable orders drive confidence in mid-term targets.EKTA
Investor update21 Nov 2025